Please provide your email address to receive an email when new articles are posted on . Tezepelumab has received an FDA breakthrough therapy designation as a maintenance treatment for patients ...

Subsequent OGD showed persistence of the mass. Repeat histology showed no evidence of malignancy but demonstrated an inflammatory cell infiltrate within the gastric mucosa with a predominance of ...